Fuso Pharmaceutical Profit Slumps Despite Modest Sales Growth

An update from Fuso Pharmaceutical Industries,Ltd. ( (JP:4538) ) is now available.

Fuso Pharmaceutical Industries reported non-consolidated net sales of ¥48.27 billion for the nine months ended December 31, 2025, up 3.4% year on year, but operating profit dropped 34.8% to ¥2.37 billion and ordinary profit fell 33.7%, with profit declining almost 30%, reflecting margin pressure despite modest revenue growth. The company’s total assets rose to ¥89.45 billion while its equity ratio slipped to 38.7%, and it maintained its dividend policy with a planned annual payout of ¥90 per share for the fiscal year ending March 31, 2026, alongside a full-year forecast of only slight sales growth and lower profits, underscoring a more challenging earnings environment for shareholders.

The most recent analyst rating on (JP:4538) stock is a Hold with a Yen2469.00 price target. To see the full list of analyst forecasts on Fuso Pharmaceutical Industries,Ltd. stock, see the JP:4538 Stock Forecast page.

More about Fuso Pharmaceutical Industries,Ltd.

Fuso Pharmaceutical Industries, Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange. It focuses on manufacturing and selling pharmaceutical products, operating under Japanese GAAP and serving the domestic healthcare market as a mid-sized drug maker with a stable shareholder return policy through dividends.

Average Trading Volume: 18,923

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen20.62B

See more data about 4538 stock on TipRanks’ Stock Analysis page.